구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CD70 CAR T-cells (CD70 CAR T-cells) Chongqing Precision Biotech Co., L…·Acute Myeloid Leukemia 31 trials |
|---|---|
Overview Program | CD70 CAR T-cells |
Overview Company | Chongqing Precision Biotech Co., Ltd |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Metastatic Tumor; Renal Cell Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | The future of cellular therapy for the treatment of renal cell carcinoma.. Systemic treatment options for renal cell carcinoma (RCC) have expanded considerably in recent years, and both tyrosine kinase inhibitors and immune checkpoint inhibitors, alone or in combination, have entered the clinical arena. Adoptive cell immunotherapies have recently revolutionized the treatment of cancer and hold the… |
Toxicology CRS | Reported |
Clinical Safety signal | The future of cellular therapy for the treatment of renal cell carcinoma.. Systemic treatment options for renal cell carcinoma (RCC) have expanded considerably in recent years, and both tyrosine kinase inhibitors and immune checkpoint inhibitors, alone or in combination, have entered the clinical arena. Adoptive cell immunotherapies have recently revolutionized the treatment of cancer and hold the… |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CD70 CAR T-cells (CD70 CAR T-cells) Chongqing Precision Biotech Co., L…·Acute Myeloid Leukemia 31 trials |
|---|---|
Overview Program | CD70 CAR T-cells |
Overview Company | Chongqing Precision Biotech Co., Ltd |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Metastatic Tumor; Renal Cell Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | The future of cellular therapy for the treatment of renal cell carcinoma.. Systemic treatment options for renal cell carcinoma (RCC) have expanded considerably in recent years, and both tyrosine kinase inhibitors and immune checkpoint inhibitors, alone or in combination, have entered the clinical arena. Adoptive cell immunotherapies have recently revolutionized the treatment of cancer and hold the… |
Toxicology CRS | Reported |
Clinical Safety signal | The future of cellular therapy for the treatment of renal cell carcinoma.. Systemic treatment options for renal cell carcinoma (RCC) have expanded considerably in recent years, and both tyrosine kinase inhibitors and immune checkpoint inhibitors, alone or in combination, have entered the clinical arena. Adoptive cell immunotherapies have recently revolutionized the treatment of cancer and hold the… |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교